Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates.
Prenafeta, A., Bech-Sàbat, G., Moros, A., Barreiro, A., Fernández, A., Cañete, M., Roca, M., González-González, L.,
Garriga, C., Confais, J., Toussenot, M., Contamin, H., Pizzorno, A., Rosa-Calatrava, M., Pradenas, E., Marfil, S., Blanco, J., Rica, P. C., Sisteré-Oró, M., Meyerhans, A., Ferrer,
L.
iScience. 2023;107224. doi:10.1016/j.isci.2023.107224 [published online ahead of print, 2023 Jun
28].
Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19.
Hocini H, Wiedemann A, Blengio F, Lefebvre C, Cervantes-Gonzalez M, Foucat E, Tisserand P, Surenaud M, Coléon S,
Prague M, Guillaumat L, Krief C, Fenwick C, Laouénan C, Bouadma L, Ghosn J, Pantaleo G, Thiébaut R; French COVID cohort study group; Lévy Y.
J Clin Immunol. 2023 Mar 21:1–12. doi: 10.1007/s10875-023-01459-x. Epub ahead of print. Erratum in: J Clin Immunol.
2023 Mar 30;: PMID: 36943669; PMCID: PMC10029801.
Prior SARS-CoV-2 infection
enhances and reshapes spike protein-specific memory induced by vaccination.
Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn MH, Allatif O, Guibert N, Compagnon C, Mariano N, Chaix J, Djebali S, Fassier JB, Lina B, Lefsihane K,
Espi M, Thaunat O, Marvel J, Rosa-Calatrava M, Pizzorno A, Maucort-Boulch D, Henaff L, Saadatian-Elahi M, Vanhems P, Paul S, Walzer T, Trouillet-Assant S, Defrance
T.
Sci Transl Med. 2023 Mar 15;15(687):eade0550. doi: 10.1126/scitranslmed.ade0550. Epub 2023 Mar 15. PMID: 36921035.
Autoantibodies against type
I IFNs in patients with critical influenza pneumonia.
Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T, Bizien L, Manry J, Rosain J, Philippot Q, Goavec K, Padey B, Cupic A, Laurent E, Saker K, Vanker M, Särekannu
K; COVID Human Genetic Effort; Etablissement Français du Sang Study Group; Constances Cohort; 3C-Dijon Study; Cerba HealthCare Group; Lyon Antigrippe Working Group; REIPI INF Working Group;
García-Salum T, Ferres M, Le Corre N, Sánchez-Céspedes J, Balsera-Manzanero M, Carratala J, Retamar-Gentil P, Abelenda-Alonso G, Valiente A, Tiberghien P, Zins M, Debette S, Meyts I, Haerynck F,
Castagnoli R, Notarangelo LD, Gonzalez-Granado LI, Dominguez-Pinilla N, Andreakos E, Triantafyllia V, Rodríguez-Gallego C, Solé-Violán J, Ruiz-Hernandez JJ, Rodríguez de Castro F, Ferreres J,
Briones M, Wauters J, Vanderbeke L, Feys S, Kuo CY, Lei WT, Ku CL, Tal G, Etzioni A, Hanna S, Fournet T, Casalegno JS, Queromes G, Argaud L, Javouhey E, Rosa-Calatrava M, Cordero E, Aydillo T,
Medina RA, Kisand K, Puel A, Jouanguy E, Abel L, Cobat A, Trouillet-Assant S, García-Sastre A, Casanova JL.
J Exp Med. 2022 Nov 7;219(11):e20220514. doi: 10.1084/jem.20220514.
Epub 2022 Sep 16. PMID: 36112363
Paediatric COVID-19
mortality: a database analysis of the impact of health resource disparity.
Marwali EM, Kekalih A, Yuliarto S, Wati DK, Rayhan M, Valerie IC, Cho HJ, Jassat W, Blumberg L, Masha M, Semple C, Swann OV, Kohns Vasconcelos M, Popielska J, Murthy S, Fowler
RA, Guerguerian AM, Streinu-Cercel A, Pathmanathan MD, Rojek A, Kartsonaki C, Gonçalves BP, Citarella BW, Merson L, Olliaro PL, Dalton HJ; International Severe Acute Respiratory and emerging
Infection Consortium (ISARIC) Clinical Characterization Group Investigators.
BMJ Paediatr Open. 2022 Oct;6(1):e001657. doi:
10.1136/bmjpo-2022-001657. PMID: 36645791
Oropharyngeal and intestinal
concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adults.
Patrier J, Villageois-Tran K, Szychowiak P, Ruckly S, Gschwind R, Wicky PH, Gueye S, Armand-Lefevre L, Marzouk M, Sonneville R, Bouadma L, Petitjean M, Lamara F, de Montmollin
E, Timsit JF, Ruppé E; French COVID Cohort Study Group.
Crit Care. 2022 Oct 3;26(1):300. doi: 10.1186/s13054-022-04164-0.
PMID: 36192756
Respiratory support in
patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study.
Reyes LF, Murthy S, Garcia Gallo E, Merson L, Ibáñez Prada E, Rello E, Fuentes Y, Martin Loeches I, Bozza F, Duque S,Taccone F, Fowler RA, Kartsonaki C, Gonçalves BP, Wanjiru
Citarella B, Aryal D, Burhan E, Cummings MJ, Delmas C, Diaz R, Figueiredo Mello C, Hashmi M, Kumar Panda P, Jiménez M, Rincon D, Thomson D, Nichol A, Marshall JC, Olliaro P and the ISARIC
Characterization Group.
Critical Care Sept 2022
26:276.
Interactions between Severe
Acute Respiratory Syndrome Coronavirus 2 Replication and Major Respiratory Viruses in Human nasal Epithelium
Pizzorno A, Padey B, Dulière V, Mouton W, Oliva J, Emilie L, Milesi C, Lina B, Traversier A, Julien T, Trouillet Assant S, Rosa-Calatrava M and Terrier O.
J Infect Dis. 2022 Aug 29:jiac357. doi: 10.1093/infdis/jiac357. Epub
ahead of print. PMID: 36031537; PMCID: PMC9452145.
ISARIC-COVID-19 dataset: A
Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19.
ISARIC Clinical Characterization Group, Garcia-Gallo1 E, Merson L, Kennon K, Kelly S, Citarella B, Vidali Fryer D, Shrapnel S, Lee J, Duque S, Fuentes Y, Balan V, Smith S, Wei
J, Gonçalves P, Russell C, Sigfrid L, Dagens A, Olliaro P, Baruch J, Kartsonaki C, Dunning J, Rojek A, Rashan A, Beane A, Murthy S, Reyes P
Scientific data 2022 Jul 30 2022; 9:
454.
The risk of COVID-19 death
is much greater and age dependent with type I IFN autoantibodies.
Manrya J, Bastard P et al., COVID Clinicians , COVID-STORM Clinicians , NIAID Immune Response to COVID Group , NH-COVAIR Study Group , Danish CHGE , Danish Blood Donor Study ,
St. James's Hospital, SARS CoV2 Interest Group , French COVID Cohort Study Group , Imagine COVID-Group , The Milieu Interieur Consortium, CoV-Contact Cohort , Amsterdam UMC Covid-19 Biobank
Investigators , COVID Human Genetic Effort , CP-COVID-19 Group, CONSTANCES cohort, 3C-Dijon Study, Cerba Health-Care, Etablissement Français du Sang Study group , Anderson M, Boisson B, Beziat V,
Zhang SY, Andreakosmm E, Hermine O, Pujol A, Petersong P, Mogensen TH, Rowenoo L, Mond J, Debette S, de Lamballerie X, Burdet C, Bouadmas L, Zins M, Soler-Palacin P, Colobran R, Gorochov G,
Solanich X, Susen S, Martinez-Picado J, Raoult D, Vass M, Gregersent PK, Piemontiv L, Rodrıguez- Gallegott C, Notarangelod LD, Sudd HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien
P, Zhang Q, Casanova JL, Abel L and Cobat A.
Proc Natl Acad Sci U S A 2022 May
24;119(21)
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Matuozzo D, Talouarn E, et al., COVID Human Genetic Effort, COVIDeF Study Group, French COVID Cohort Study Group, CoV-
Contact Cohort, COVID-STORM Clinicians, COVID Clinicians, Orchestra Working Group, Amsterdam UMC Covid-19 Biobank, NIAID-USUHS COVID Study Group, Meyts I, Zhang SY, Puel A,
Notarangelo LD, Boisson-Dupuis S, Su HC, Boisson B, Jouanguy E, Casanova JL, Zhang Q, Abel L and Cobat A.
July 2022 Accepted in Journal of Clinical Investigation.
Potent human broadly
SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C, Fernandez I, Bruel B, Dias de Melo G, Prot M, Beretta M,el at., French COVID Cohort Study Group, Rey FA, Schwartz O, and Mouquet
H
J Exp Med. 2022 Jul 4;219(7):e20220638. doi: 10.1084/jem.20220638. Epub
2022 Jun 15.
Molnupiravir combined with
different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Jonsdottir HR, Siegrist D, Julien T, Padey T, Bouveret M, Terrier O, Pizzorno A, Huang S, Samby K, Wells TNC, Boda B#, Rosa-Calatrava M#, Engler
O# and Constant S#.
Biomedicine & Pharmacotherapy 150 Volume 150 June 2022, 113058. #Equal contribution.
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.
Bastard P, Vazquez S, Liu J, Laurie MT, Wang CY, Gervais A, Le Voyer T, Bizien L, Zamecnik C, Philippot Q, Rosain J, Catherinot E, Willmore A, Mitchell AM, Bair R, Garçon
P, Kenney H, Fekkar A, Salagianni M, Poulakou G, Siouti E, Sahanic S, Tancevski I, Weiss G, Nagl L, Manry J, Duvlis S, Arroyo-Sánchez D, Paz Artal E, Rubio L, Perani C, Bezzi M, Sottini A,
Quaresima V, Roussel L, Vinh DC, Reyes LF, Garzaro M, Hatipoglu N, Boutboul D, Tandjaoui-Lambiotte Y, Borghesi A, Aliberti A, Cassaniti I, Venet F, Monneret G, Halwani R, Sharif-Askari NS,
Danielson J, Burrel S, Morbieu C, Stepanovskyy Y, Bondarenko A, Volokha A, Boyarchuk O, Gagro A, Neuville M, Neven B, Keles S, Hernu R, Bal A, Novelli A, Novelli G, Saker K, Ailioaie O, Antolí A,
Jeziorski E, Rocamora-Blanch G, Teixeira C, Delaunay C, Lhuillier M, Le Turnier P, Zhang Y, Mahevas M, Pan-Hammarström Q, Abolhassani H, Bompoil T, Dorgham K; COVID HGE consortium †; French COVID
study group †; COMET consortium †; Gorochov G, Laouenan C, Rodríguez-Gallego C, Ng LFP, Renia L, Pujol A, Belot A, Raffi F, Allende LM, Martinez-Picado J, Ozcelik T, Keles S, Imberti L,
Notarangelo LD, Troya J, Solanich X, Zhang SY, Puel A, Wilson MR, Trouillet-Assant S, Abel L, Jouanguy E, Ye CJ, Cobat A, Thompson LM, Andreakos E, Zhang Q, Anderson MS, Casanova JL, DeRisi
JL.
Sci Immunol. 2022 Jun 14:eabp8966. doi: 10.1126/sciimmunol.abp8966. Online ahead of print. PMID:
35857576
The risk of COVID-19 death
is much greater and age dependent with type I IFN autoantibodies.
Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M,
Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon
P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Mégarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM,
Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs CM, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Anglicheau D, Planas AM,
Haerynck F, Duvlis S, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V,
Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D,
Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R,
Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari FS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira
F, Roussel L, Vinh DC, Erikstrup C, Condino-Neto A, Prando C, Bondarenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM
Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital, SARS CoV2 Interest Group; French COVID Cohort Study Group;
Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank Investigators; COVID Human Genetic Effort; CP-COVID-19 Group; CONSTANCES cohort; 3C-Dijon
Study; Cerba Health-Care; Etablissement Français du Sang Study group; Anderson MS, Boisson B, Béziat V, Zhang SY, Andreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J,
Debette S, de Lamballerie X, Burdet C, Bouadma L, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L,
Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Casanova JL, Abel L, Cobat A.
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119. doi: 10.1073/pnas.2200413119. Epub 2022 May 16. PMID:
35576468
Molnupiravir combined with
different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Hulda R. Jonsdottir, Denise Siegrist, Thomas Julien, Blandine Padey, Mendy Bouveret, Olivier Terrier, Andres Pizzorno, Song Huang, Kirandeep Samby, Timothy N.C. Wells,
Bernadett Boda, Manuel Rosa-Calatrava, Olivier B. Engler, Samuel Constant.
Biomedicine & Pharmacotherapy, Volume 150, 2022, 113058, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2022.113058.
Antiviral efficacy of
favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, Naninck T, Pascal Q, Behillil S, Maisonnasse P, Lemaitre J, Kahlaoui N, Delache B, Pizzorno A, Nougairede A,
Ludot C, Terrier O, Dereuddre-Bosquet N, Relouzat A, Chapon C, Ho Tsong Fang R, van der Werf S, Rosa Calatrava M, Malvy D, de Lamballerie X, Guedj J & Le Grand R.
March 2022 Nature Communications volume 13, Article number: 5108
(2022).
Evaluation of Commercial
Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers.
Saker K, Escuret V, Pitiot V, Massardier-Pilonchéry A, Paul S, Mokdad B, Langlois-Jacques C, Rabilloud M, Goncalves D, Fabien N, Guibert N, Fassier JB, Bal A, Trouillet-Assant
S, Trabaud MA.
J Clin Microbiol. 2022 Jan 19;60(1):e0174621. doi: 10.1128/JCM.01746-21. Epub 2021 Oct 27. PMID: 34705539
Greater age-dependent risk of COVID-19 death with type I IFN autoantibodies
New England Journal of Medicine Jan 2022 14;rs.3.rs-1225906.
Immunogenicity and efficacy
of heterologous ChAdOx1-BNT162b2 vaccination.
Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, Peyrot L, Allatif O, Fassier JB, Massardier-Pilonchéry A, Brengel-Pesce K, Yaugel-Novoa M, Denolly S, Boson
B, Bourlet T, Bal A, Valette M, Andrieu T, Lina B; Covid-Ser study group; Cosset FL, Paul S, Defrance T, Marvel J, Walzer T, Trouillet-Assant S.
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21. PMID: 34673755
Chronic use of
renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.
Gault N, Esposito-Farèse M, Revest M, Inamo J, Cabié A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, De Montmollin
E, Oziol E, Etienne M, Laouénan C, Rossignol P, Costagliola D, Vidal-Petiot E; French-Covid cohort investigators, study group.
Fundam Clin Pharmacol. 2021 Dec;35(6):1141-1158. doi: 10.1111/fcp.12683. Epub 2021 May 16. PMID: 33876439
Chronic use of
renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review.
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard E, Hulot JS, Ghosn J, Chirouze C, Deconinck L, French COVID Cohort Study Group.
Fundamental & clinical pharmacology Dec 2021 Vol 35 issue 6 p1141-1158.
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges.
Terrier O, Si-Tahar M, Ducatez M, Chevalier C, Pizzorno A, Le Goffic R, Crépin T, Simon G, Naffakh
N.
PLoS Pathog. 2021 Dec 30;17(12):e1010106. doi: 10.1371/journal.ppat.1010106. PMID: 34969061; PMCID:PMC8718010.
Flagellin From Pseudomonas aeruginosa Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by Increasing TMPRSS2
Expression.
Ruffin M, Bigot J, Calmel C, Mercier J, Givelet M, Oliva J, Pizzorno A, Rosa-Calatrava M, Corvol H, Balloy V,
Terrier O, Guillot L.
Front Immunol. 2021 Dec 7;12:714027. doi: 10.3389/fimmu.2021.714027. PMID: 34950129; PMCID: PMC8688244.
Greater age-dependent risk of COVID-19 death with type I IFN autoantibodies.
Manry J, Bastard P, et al, COVID-STORM Clinicians, NIAID Immune Response to COVID Group, NH-COVAIR Study Group,
Danish CHGE, Danish Blood Donor Study, St. James's Hospital, SARS CoV2 Interest group, French COVID Cohort Study Group, Imagine COVID-Group, The Milieu Intérieur Consortium, CoV-Contact Cohort,
Amsterdam UMC Covid-19 Biobank Investigators, COVID Human Genetic Effort, CONSTANCES cohort, 3C-Dijon Study, Cerba Health-Care, Etablissement du Sang study group, Casanova JL, Abel L, and Cobat
A.
Dec 2021, Accepted in New England Journal of Medicine.
Ten months of temporal
variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort.
ISARIC Clinical Characterisation Group; Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, Dankwa EA, Donnelly
CA, Dunning J, Escher M, Kartsonaki C, Merson L, Pritchard M, Wei J, Horby PW, Rojek A, Olliaro PL.
Elife. 2021 Nov 23;10:e70970. doi:
10.7554/eLife.70970. PMID: 34812731
Avian Cell Line
DuckCelt®-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac®.
Chupin C, Pizzorno A, Traversier A, Brun P, Ogonczyk-Makowska D, Padey B, Milesi C, Dulière V, Laurent E, Julien
T, Galloux M, Lina B, Eléouët JF, Moreau K, Hamelin ME, Terrier O, Boivin G, Dubois J, Rosa-Calatrava M.
Vaccines (Basel). 2021 Oct 16;9(10):1190. doi: 10.3390/vaccines9101190. PMID: 34696298; PMCID:
PMC8540687.
Hamster organotypic modeling
of SARS-CoV-2 lung and brainstem infection.
Ferren M, Favède V, Decimo D, Iampietro M, Lieberman NAP, Weickert JL, Pelissier R, Mazelier M, Terrier O, Moscona A, Porotto M, Greninger AL, Messaddeq N, Horvat B, Mathieu
C.
Nat Commun. 2021 Oct 4;12(1):5809. doi: 10.1038/s41467-021-26096-z. PMID: 34608167; PMCID: PMC8490365.
Early nasal type I IFN
immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.
Lopez J,
Mommert M, Mouton W, Pizzorno A, Brengel-Pesce K, Mezidi M, Villard M, Lina B, Richard JC, Fassier JB, Cheynet V, Padey B, Duliere V, Julien T, Paul S, Bastard P, Belot A, Bal A, Casanova JL,
Rosa-Calatrava M, Morfin F, Walzer T, Trouillet-Assant S.
J Exp Med. 2021
Oct 4;218(10):e20211211. doi: 10.1084/jem.20211211. Epub 2021 Aug 6. PMID: 34357402.
Sera Neutralizing Activities
Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.
Betton M,
Livrozet M, Planas D, Fayol A, Monel B, Védie B, Bruel T, Tartour E, Robillard N, Manuguerra JC, Blanchard A, Ghosn J, Visseaux B, Péré H, Lebeaux D, Schwartz O, Veyer D, Hulot JS; French COVID
Cohort Study Group.
Clin Infect
Dis. 2021 Sep 15;73(6):e1337-e1344. doi: 10.1093/cid/ciab308. PMID: 33851216
Autoantibodies neutralizing type I IFNs are present in ~4% of
uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Bastard P, Gervais A, Le Voyer T, Rosain J,
Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y,
Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio
T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R,
Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S,
Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E,
Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY,
Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters
J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR,
Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to
COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur
Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group;
Anderson MS, Boisson B, Béziat V, Zhang SY, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler-Palacin P,
Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E,
Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova JL.
Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340. PMID: 34413139
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
Asano T, Boisson B,
Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, Zhang P, Meertens L, Bolze A, Materna M, Korniotis S, Gervais A, Talouarn E, Bigio B, Seeleuthner Y, Bilguvar K, Zhang Y, Neehus
AL, Ogishi M, Pelham SJ, Le Voyer T, Rosain J, Philippot Q, Soler-Palacín P, Colobran R, Martin-Nalda A, Rivière JG, Tandjaoui-Lambiotte Y, Chaïbi K, Shahrooei M, Darazam IA, Olyaei NA, Mansouri
D, Hatipoğlu N, Palabiyik F, Ozcelik T, Novelli G, Novelli A, Casari G, Aiuti A, Carrera P, Bondesan S, Barzaghi F, Rovere-Querini P, Tresoldi C, Franco JL, Rojas J, Reyes LF, Bustos IG, Arias
AA, Morelle G, Christèle K, Troya J, Planas-Serra L, Schlüter A, Gut M, Pujol A, Allende LM, Rodriguez-Gallego C, Flores C, Cabrera-Marante O, Pleguezuelo DE, de Diego RP, Keles S, Aytekin G,
Akcan OM, Bryceson YT, Bergman P, Brodin P, Smole D, Smith CIE, Norlin AC, Campbell TM, Covill LE, Hammarström L, Pan-Hammarström Q, Abolhassani H, Mane S, Marr N, Ata M, Al Ali F, Khan T, Spaan
AN, Dalgard CL, Bonfanti P, Biondi A, Tubiana S, Burdet C, Nussbaum R, Kahn-Kirby A, Snow AL; COVID Human Genetic Effort; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French
COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-; Biobank; NIAID-USUHS COVID Study Group; Bustamante J, Puel A, Boisson-Dupuis S, Zhang SY, Béziat V, Lifton RP, Bastard P,
Notarangelo LD, Abel L, Su HC, Jouanguy E, Amara A, Soumelis V, Cobat A, Zhang Q, Casanova JL.
Sci Immunol. 2021 Aug 19;6(62):eabl4348. doi: 10.1126/sciimmunol.abl4348. PMID:
34413140
Refining "Long-COVID" by a
Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection.
Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, Mengin A, Gras A, Vidailhet P, Arnould-Michel R, Bibi-Triki S, Carapito R,
Trouillet-Assant S, Perret M, Belot A, Bahram S, Arnaud L, Gottenberg JE, Fafi-Kremer S, Sibilia J.
Infect Dis Ther. 2021 Sep;10(3):1747-1763. doi: 10.1007/s40121-021-00484-w. Epub 2021 Jul 10. PMID: 34245450
Six-month antibody response
to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.
Bal A, Trabaud MA, Fassier JB, Rabilloud M,
Saker K, Langlois-Jacques C, Guibert N, Paul A, Alfaiate D, Massardier-Pilonchery A, Pitiot V, Morfin-Sherpa F, Lina B, Pozzetto B, Trouillet-Assant S; COVID SER Study Group.
Clin Microbiol Infect. 2021 Jun;27(6):933-935.
doi: 10.1016/j.cmi.2021.01.003. Epub 2021 Jan 13. PMID: 33450388
Antiviral properties of the NSAID drug naproxen Targeting the nucleoprotein
of SARS-CoV-2 Coronavirus
Terrier O, Dilly S, Pizzorno A, Chalupska D,
Humpolickova J, Bouřa B, Berenbaum F, Quideau S, Lina B, Feve B, Adnet F, Sabbah M, Rosa-Calatrava M, Maréchal V, Henri J, Slama-Schwok A.
Molecules 2021, 26(9), 2593
Structural
insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia
Bei Wang, Daniel Asarnow, Wen-Hsin Lee#, Ching-Wen Huang#, Bryan Faust#, Patricia Miang Lon Ng#, Eve Zi Xian Ngoh#, Markus Bohn#,
David Bulkley#, Andrés Pizzorno*#, Hwee Ching Tan, Chia Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek Kheng
Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang.
#Equal contribution
Cell, April 23, 2021
Modeling SARS-CoV-2 viral
kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Néant N, Lingas
G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C,
Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J; French COVID Cohort
Investigators and French Cohort Study groups.
Proc Natl Acad
Sci U S A. 2021 Feb 23;118(8):e2017962118. doi: 10.1073/pnas.2017962118. PMID: 33536313; PMCID: PMC7929555.
SARS-CoV-2
viral dynamics in non-human primates.
Antonio Gonçalves, Pauline
Maisonnasse, Flora Donati, Mélanie Albert, Sylvie Behillil, Vanessa Contreras, Thibaut Naninck, Romain Marlin, Caroline Solas, Andres Pizzorno, Julien Lemaitre, Nidhal Kahlaoui, Olivier Terrier,
Raphael Ho Tsong Fang, Vincent Enouf, Nathalie Dereuddre-Bosquet, Angela Brisbarre, Franck Touret, Catherine Chapon, Bruno Hoen, Bruno Lina, Manuel Rosa-Calatrava, Xavier de Lamballerie, France
Mentré, Roger Le Grand, Sylvie van der Werf, Jeremie Guedj.
PLOS Computational Biology.
Accepted Feb 2021
Transcriptional Profiling of
Immune and Inflammatory Responses in the Context of SARS-CoV-2 Fungal Superinfection in a Human Airway Epithelial Model.
Nicolas de Lamballerie C, Pizzorno A, Fouret
J, Szpiro L, Padey B, Dubois J, Julien T, Traversier A, Dulière V, Brun P, Lina B, Rosa-Calatrava M, Terrier O.
Microorganisms. 2020 Dec 11;8(12):1974. doi:
10.3390/microorganisms8121974.PMID: 33322535
Detection of SARS-CoV-2
N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Hingrat QL, Visseaux B, Laouenan C, Tubiana S,
Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N; French COVID cohort management
committee, CoV-CONTACT study group; members of the French-COVID cohort study group (by alphabetical order); member of the CoV-CONTACT study group. Principal investigator; Steering Committee;
CoV-CONTACT Clinical Centers; Coordination and statistical analyses; Virological Lab; Biological Center; Partners; Sponsor; Genetic.
Clin Microbiol Infect. 2020 Dec
8:S1198-743X(20)30721-7. doi: 10.1016/j.cmi.2020.11.025.
In Vitro Combinations of
Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Checkmahomed L, Padey B, Pizzorno A, Terrier O, Rosa-Calatrava M, Abed Y, Baz M, Boivin G.
Viruses. 2020 Oct 8;12(10):1139. doi: 10.3390/v12101139.PMID: 33049959
Type
I IFN immunoprofiling in COVID-19 patients.
Trouillet-Assant S,
Viel S, Gaymard A, Pons S, Richard JC, Perret M, Villard M, Brengel-Pesce K, Lina B, Mezidi M, Bitker L, Belot A; COVID HCL Study group.
Allergy Clin Immunol.
2020 Jul;146(1):206-208. doi: 10.1016/j.jaci.2020.04.029. Epub 2020 Apr 29. PMID: 32360285
Human Respiratory Syncytial
Virus-induced immune signature of infection revealed by transcriptome analysis of clinical pediatric nasopharyngeal swab samples.
Nicolas De
Lamballerie C, Pizzorno A, Dubois J, Padey B, Julien T, Traversier A, Carbonneau J, Orcel E, Lina B, Hamelin ME, Roche M, Textoris J, Boivin G, Legras-Lachuer C, Terrier O, Rosa-Calatrava
M.
bioRxiv 2020.05.20.106492; doi: https://doi.org/10.1101/2020.05.20.106492, Accepted in Journal of Infectious Disease.
Characterization
and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia.
Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, Fouret J, Dubois J, Gaymard A, Lescure FX, Dulière V, Brun P, Constant S, Poissy J, Lina B,
Yazdanpanah Y, Terrier O and Rosa-Calatrava M.
Cell Reports Medecine Volume 1, Issue 4, 21 July 2020, 100059, doi: 10.1016/j.xcrm.2020.100059
Hydroxychloroquine use against SARS-CoV-2 infection in non-human
primates.
Maisonnasse P, Guedj J, Contreras V, Behillil
S, Solas C, Marlin R, Naninck T, Pizzorno A, Lemaitre J, Gonçalves A, Kahlaoui N, Terrier O, Fang RHT, Enouf V, Dereuddre-Bosquet N, Brisebarre A, Touret F, Chapon C, Hoen B, Lina B, Calatrava
MR, van der Werf S, de Lamballerie X, Le Grand R.
Nature. 2020 Jul 22. doi:
10.1038/s41586-020-2558-4.
Timing of Antiviral Treatment Initiation is Critical to Reduce
SARS-CoV-2 Viral Load.
Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J.
CPT Pharmacometrics Syst Pharmacol. 2020 Jun 18:10.1002/psp4.12543. doi: 10.1002/psp4.12543.
Influenza infection rewires
energy metabolism and induces browning features in adipose cells and tissues.
Ayari A, Rosa-Calatrava M, Lancel S,
Barthelemy J, Pizzorno A, Mayeuf-Louchart A, Baron M, Hot D, Deruyter L, Soulard D, Julien T, Faveeuw C, Molendi-Coste O, Dombrowicz D, Sedano L, Sencio V, Le Goffic R, Trottein F, Wolowczuk
I.
Commun Biol. 2020 May 14;3(1):237. doi:
10.1038/s42003-020-0965-6. PMID: 32409640; PMCID: PMC7224208.
Strain-Dependent Impact of G and SH Deletions Provide New Insights for
Live-Attenuated HMPV Vaccine Development.
Dubois J, Pizzorno A, Cavanagh MH, Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne S, Couture C, Lina B,
Hamelin ME, Terrier O, Rosa-Calatrava M and Boivin G.
Vaccines 2019, 7(4), 164; https://doi.org/10.3390/vaccines7040164 Published: 30 October 2019.
Novel calixarene-based
surfactant enables low dose split inactivated vaccine protection against influenza infection.
Mandon ED, Pizzorno A, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M, Jawhari A.
Vaccine. 2019 Oct 17. pii: S0264-410X(19)31381-7. doi: 10.1016/j.vaccine.2019.10.018.
Characterization of cellular
transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia.
Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O & Rosa-Calatrava
C.
Scientific Reports. 2019 Aug 7; 9: 11493. doi: 10.1038/s41598-019-48013.
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of
oseltamivir.
Georgel AF, Cayet D, Pizzorno A, Rosa-Calatrava M, Paget C, Sencio V, Dubuisson J, Trottein F, Sirard JC, Carnoy C.
Antiviral Res. 2019 May 9;168:28-35. doi: 10.1016/j.antiviral.2019.05.002.
Human metapneumovirus activates NOD-like
receptor protein 3 inflammasome via its small hydrophobic protein which plays a detrimental role during infection in mice.
Lê VB, Dubois J, Couture C, Cavanagh MH, Uyar O, Pizzorno A, Rosa-Calatrava M, Hamelin MÈ, Boivin G.
Front Immunol. 2019 Mar 19;10:531. doi: 10.3389/fimmu.2019.00531. eCollection 2019
Drug
repurposing approaches for the treatment of influenza viral infection: Reviving old drugs to fight against a long-lived enemy.
Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M.
Front Immunol. 2019 Mar 19;10:531. doi: 10.3389/fimmu.2019.00531. eCollection 2019
Repurposing of drugs as novel influenza
inhibitors from clinical gene expression infection signatures.
Pizzorno A,Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rheaume C, Croze S, Escuret V, Poissy J, Lina B,
Legras-Lachuer C, Textoris J, Boivin G and Rosa-Calatrava M.
Front Immunol. 2019 Jan 29;10:60. doi: 10.3389/fimmu.2019.00060. eCollection 2019.
The non-structural NS1 protein of influenza viruses modulates TP53 splicing through the host factor CPSF4.
Dubois J, Traversier A, Julien T, Padey B, Lina B, Bourdon JC, Marcel V, Boivin G, Rosa-Calatrava M and Terrier O.
J Virol. 2019 Mar 21;93(7). pii: e02168-18. doi: 10.1128/JVI.02168-18. Print 2019 Apr 1.
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
Del Campo J, Pizzorno MA, Djebali S, Bouley J, Haller M, Perez-Vargas J, Lina B, Boivin G, Hamelin ME, Nicolas F, Le Vert A, Leverrier Y, Rosa-Calatrava M, Marvel J
and Hill F.
NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4.
eCollection 2019.
Influenza viruses production: Evaluation of a
novel avian cell line DuckCelt®-T17.
Petiot E, Proust A, Traversier A, Durous L, Dappozze F, Gras M, Guillard C, Balloul JM, Rosa-Calatrava M.
Vaccine. 2018 May 24;36(22):3101-3111. doi:10.1016/j.vaccine.2017.03.102. Epub 2017 May 29. PubMed PMID: 28571695.
Influenza
A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection.
Pizzorno A, Dubois J, Machado D, Cartet G, Traversier A, Julien T, Lina B, Bourdon JC, Rosa-Calatrava M, and Terrier O.
Sci Rep. 2018 Feb 27 ;8(1):3746. doi: 10.1038/s41598-018-22139-6.
Development and pre-clinical evaluation in the swine model of a mucosal vaccine tablet for human influenza viruses: A proof-of-concept study.
Busignies V, Simon G, Mollereau G, Bourry O, Mazel V, Rosa-Calatrava M and Tchoreloff P.
Int J Pharm. 2018 Mar 1;538(1-2):87-96. doi:
10.1016/j.ijpharm.2018.01.021.
RSV infection in human macrophages
promotes CXCL10/IP-10 expression during bacterial co-infection.
Machado D, Hoffmann J, Moroso M, Rosa-Calatrava M, Endtz H, Terrier O, Paranhos-Bacala.
Int J Mol Sci. 2017 Dec 7;18(12). pii: E2654. doi:
10.3390/ijms18122654.
Generation of monoclonal pan-hemagglutinin
antibodies against multiple strains of influenza.
Manceur AP, Zou W, Marcil A, Paquet E, Gadoury C, Jaentschke B, Li X, Petiot E,, Durocher Y, Baardsnes J, Rosa-Calatrava M, Ansorge S and Kamen
AA.
PLoS One. 2017 Jun 29;12(6):e0180314. doi:10.1371/journal.pone.0180314. eCollection 2017. PubMed PMID: 28662134;
PubMed Central PMCID: PMC5491208.
Accelerated Mass Production of Influenza Virus Seed Stocks in
HEK-293 Suspension Cell Cultures by Reverse Genetics.
Milián E, Julien T, Biaggio R, Venereo-Sanchez A, Montes J, Manceur A, Ansorge S, Petiot E, Rosa-Calatrava M, Kamen A.
Vaccine. 2017 May 8. pii: S0264-410X(17)30557-1.
The NS1 protein from influenza virus
stimulates translation initiation by enhancing ribosome recruitment to mRNAs.
Panthu B., Terrier O., Carron C., Traversier A., Corbin A., Balvay L., Lina B., Rosa-Calatrava M. and Ohlmann T.
Journal of Molecular Biology. 2017 April 20. pii: S0022-2836(17)30182-1. doi: 10.1016/j.jmb.2017.04.007
Influenza viruses production: evaluation of a novel avian cell
line DUCKCELT®-T17.
Petiot E., Proust A., Traversier A., Durous L., Dappozze F., Gras M., Guillard C., Balloul J-M. and Rosa-Calatrava M.
Vaccine. 2017 May 29. pii: S0264-410X(17)30502-9. doi: 10.1016/j.vaccine.2017.03.102.
Mutations in the fusion
protein heptad repeat domains of human metapneumovirus impact the formation of syncytia.
Dubois J., Cavanagh M-H., Terrier O., Hamelin M-E., Lina B., Shi R.,Rosa-Calatrava M. and Boivin G.
J Gen Virol. 2017 Jun;98(6):1174-1180. doi: 10.1099/jgv.0.000796. Epub 2017 Jun 14. PubMed PMID: 28613142.
Expression and purification of
native and functional influenza A virus matrix 2 proton selective ion channel.
Desuzinge Mandon E, Traversier A, Champagne A, Bernier L, Audebert S, Balme S, Dejean E, Rosa-Calatrava M and A Jawhari.
Protein Expression and Purification. 2016 Nov 5;131:42-50. doi: 10.1016/j.pep.2016.11.001.
Viral and bacterial co-infection in severe pneumonia triggers innate immune responses and specifically enhances IP-10: a translational study.
Hoffmann J, Machado D, Terrier O, Pouzol S, Messaoudi M, Basualdo W, Espínola EE, Guillen RM, Rosa-Calatrava M, Picot V,Bénet T, Endtz H, Russomando G,
Paranhos-Baccalà G.
Scientific Reports. 2016 Dec 6;6:38532. doi: 10.1038/srep38532.
Critical phases of viral production processes monitored
by capacitance.
Petiot E, Ansorge S, Rosa-Calatrava M, and Kamen AA.
Journal of Biotechnology. 2017 Jan 20;242:19-29. doi: 10.1016/j.jbiotec.2016.11.010.
Immune signatures of protective spleen memory CD8 T
cells.
Brinza L, Djebali S, Tomkowiak M, Mafille J, Loiseau C, Jouve PE, Bernard S, Buffat L, Lina B, Ottmann M, Rosa-Calatrava M, Schicklin S, Bonnefoy N, Lauvau G, Grau
G, Wencker M, Arpin C, Walzer T, Leverrier Y, and Marvel J.
Scientific Report. 2016 Nov 24;6:37651. doi: 10.1038/srep37651
Nucleolin interacts with influenza A nucleoprotein and contributes to viral ribonucleoprotein complexes nuclear trafficking and efficient influenza viral
replication.
Terrier O, Carron C, De Chassey B, Dubois J, Traversier A, Julien T, Cartet G, Proust A, Hacot S, Ressnikof D, Lotteau V, Lina B, Diaz JJ, Moules V and
Rosa-Calatrava M.
Scientific Report. 2016 Jul 4;6:29006. doi: 10.1038/srep29006.
Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group-2 neuraminidase (N2, N3, N6, N7, N9).
Gaymard A, Charles-Dufant A, Sabatier M, Cortay JC, Frobert E, Picard C, Casalegno JS, Rosa-Calatrava M, Ferraris O, Valette M, Ottmann M, Lina B and Escuret
V.
Journal of Antimicrobial Chemotherapy. 2016 July 7. DOI: 10.1093/jac/dkw275
Modulation of transcriptomic signature of the infected host: a new therapeutic strategy for the management of severe viral infections? Example of the flu.
Poissy J, Terrier O, Lina B, Textoris J, Rosa-Calatrava M.
Reanimation 2016 March 25 (2016) S53-S61.
Petiot E, Cuperlovic-Culf M, Shen CF, Kamen A.
Vaccine. 2015 Nov 4;33(44):5974-81. doi: 10.1016/j.vaccine.2015.05.097. Epub 2015 Jun 11.
Critical
assessment of influenza VLP production in Sf9 and HEK293 expression systems.
Thompson CM, Petiot E, Mullick A, Aucoin MG, Henry O, Kamen A.
BMC Biotechnol. 2015 May 16;15:31. doi: 10.1186/s12896-015-0152-x.
Influenza viruses and mRNA splicing: doing more with
less.
Dubois J, Terrier O, Rosa-Calatrava M.
MBio. 2014 May 13;5(3):e00070-14. doi: 10.1128/mBio.00070-14.
Selective packaging of the influenza A
genome and consequences for genetic reassortment.
Gerber M, Isel C, Moules V, Marquet R
Trends Microbiol. 2014 Aug;22(8):446-55. doi: 10.1016/j.tim.2014.04.001. Epub 2014 May 2.
Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.
Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC.
Cell Death Differ. 2014 Sep;21(9):1377-87. doi: 10.1038/cdd.2014.73. Epub 2014 Jun 13.
Ultrastructural fingerprints of
avian influenza A (H7N9) virus in infected human lung cells.
Terrier O, Carron C, Cartet G, Traversier A, Julien T, Valette M, Lina B, Moules V, Rosa-Calatrava M.
Virology. 2014 May;456-457:39-42. doi: 10.1016/j.virol.2014.03.013. Epub 2014 Mar 28.
A functional sequence-specific
interaction between influenza A virus genomic RNA segments.
Gavazzi C, Yver M, Isel C, Smyth RP, Rosa-Calatrava M, Lina B, Moulès V, Marquet R.
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16604-9. doi: 10.1073/pnas.1314419110. Epub 2013 Sep 25.
Influenza NS1
interacts with p53 and alters its binding to p53-responsive genes, in a promoter-dependent manner.
Terrier O, Diederichs A, Dubois J, Cartet G, Lina B, Bourdon JC, Rosa-Calatrava M.
FEBS Lett. 2013 Sep 17;587(18):2965-71. doi: 10.1016/j.febslet.2013.08.006. Epub 2013 Aug 13.
Critical role of
segment-specific packaging signals in genetic reassortment of influenza A viruses.
Essere B, Yver M, Gavazzi C, Terrier O, Isel C, Fournier E, Giroux F, Textoris J, Julien T, Socratous C, Rosa-Calatrava M, Lina B, Marquet R, Moules V.
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):E3840-8. doi: 10.1073/pnas.1308649110. Epub 2013 Sep 16.
Characterization of a key residue for hyperfusogenic phenotype in human parainfluenza virus type 2 (hPIV-2) fusion glycoprotein.
Le Bayon JC1, Terrier O, Cartet G, Lina B, Rosa-Calatrava M.
Virus Genes. 2013 Oct;47(2):365-9. doi: 10.1007/s11262-013-0932-0. Epub 2013 Jun 8.
Extracellular HSP27 mediates angiogenesis through
Toll-like receptor 3.
Thuringer D, Jego G, Wettstein G, Terrier O, Cronier L, Yousfi N, Hébrard S, Bouchot A, Hazoumé A, Joly AL, Gleave M, Rosa-Calatrava M, Solary E, Garrido C.
FASEB J. 2013 Oct;27(10):4169-83. doi: 10.1096/fj.12-226977. Epub 2013 Jun 26.
p53 protein isoforms: key regulators in the
front line of pathogen infections?
Terrier O, Bourdon JC, Rosa-Calatrava M.
PLoS Pathog. 2013;9(4):e1003246. doi: 10.1371/journal.ppat.1003246. Epub 2013 Apr 4.
Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a.
Terrier O, Textoris J, Carron C, Marcel V, Bourdon JC, Rosa-Calatrava M.
J Gen Virol. 2013 May;94(Pt 5):985-95. doi: 10.1099/vir.0.049528-0. Epub 2013 Jan 23.
Innovative
germicidal UV and photocatalytic system dedicated to aircraft cabin eliminates volatile organic compounds and pathogenic micro-organisms.
Gorvel L, Yver M, Robert E, Harmant M, Rosa-Calatrava M, Lina B, Pierre Gorvel JP, Moulès V, Albalate R, Gaüzère C.
CLEAN - Soil, Air, WaterVolume 42, Issue 6, Article first published online: 20 OCT 2013. doi: 10.1002/clen.201300085
Interaction network linking the human H3N2
influenza A virus genomic RNA segments.
Fournier E, Moules V, Essere B, Paillart JC, Sirbat JD, Cavalier A, Rolland JP, Thomas D, Lina B, Isel C, Marquet R.
Vaccine. 2012 Dec 7;30(51):7359-67. doi: 10.1016/j.vaccine.2012.09.079. Epub 2012 Oct 9.
An in vitro network of intermolecular interactions between viral RNA segments of an avian H5N2 influenza A virus: comparison with a human H3N2 virus.
Gavazzi C, Isel C, Fournier E, Moules V, Cavalier A, Thomas D, Lina B, Marquet R.
Nucleic Acids Res. 2013 Jan;41(2):1241-54. doi: 10.1093/nar/gks1181. Epub 2012 Dec 5.
The influenza fingerprints: NS1 and M1 proteins contribute to specific host cell ultrastructure signatures upon infection by different influenza A viruses.
Terrier O, Moules V, Carron C, Cartet G, Frobert E, Yver M, Traversier A, Wolff T, Riteau B, Naffakh N, Lina B, Diaz JJ, Rosa-Calatrava M.
Virology. 2012 Oct 10;432(1):204-18. doi: 10.1016/j.virol.2012.05.019. Epub 2012 Jul 6.
Nucleolar localization of a netrin-1 isoform
enhances tumor cell proliferation.
Delloye-Bourgeois C, Goldschneider D, Paradisi A, Therizols G, Belin S, Hacot S, Rosa-Calatrava M, Scoazec JY, Diaz JJ, Bernet A, Mehlen P.
Sci Signal. 2012 Aug 7;5(236):ra57. doi: 10.1126/scisignal.2002456.
Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC.
J Virol. 2012 Aug;86(16):8452-60. doi: 10.1128/JVI.07143-11. Epub 2012 May 30.
Post-mitotic dynamics of pre-nucleolar
bodies is driven by pre-rRNA processing.
Carron C, Balor S, Delavoie F, Plisson-Chastang C, Faubladier M, Gleizes PE, O'Donohue MF.
J Cell Sci. 2012 Oct 1;125(Pt 19):4532-42. doi: 10.1242/jcs.106419. Epub 2012 Jul 5.
Recent developments with live-attenuated recombinant
paramyxovirus vaccines.
Le Bayon JC, Lina B, Rosa-Calatrava M, Boivin G.
Rev Med Virol. 2013 Jan;23(1):15-34. doi: 10.1002/rmv.1717. Epub 2012 May 8.
Ten years of human metapneumovirus research.
Feuillet F, Lina B, Rosa-Calatrava M, Boivin G.
J Clin Virol. 2012 Feb;53(2):97-105. doi: 10.1016/j.jcv.2011.10.002. Epub 2011 Nov 9.
The chicken
chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.
Durupt F, Koppers-Lalic D, Balme B, Budel L, Terrier O, Lina B, Thomas L, Hoeben RC, Rosa-Calatrava M.
Cancer Gene Ther. 2012 Jan;19(1):58-68. doi: 10.1038/cgt.2011.68. Epub 2011 Oct 21.
A supramolecular assembly formed by influenza A
virus genomic RNA segments.
Fournier E, Moules V, Essere B, Paillart JC, Sirbat JD, Isel C, Cavalier A, Rolland JP, Thomas D, Lina B, Marquet R.
Nucleic Acids Res. 2012 Mar;40(5):2197-209. doi: 10.1093/nar/gkr985. Epub 2011 Nov 10.
Measurement of enzymatic activity and specificity of human and avian influenza neuraminidases from whole virus by glycoarray and MALDI-TOF mass spectrometry.
Pourceau G, Chevolot Y, Goudot A, Giroux F, Meyer A, Moulés V, Lina B, Cecioni S, Vidal S, Yu H, Chen X, Ferraris O, Praly JP, Souteyrand E, Vasseur JJ, Morvan
F.
Chembiochem. 2011 Sep 5;12(13):2071-80. doi: 10.1002/cbic.201100128. Epub 2011 Jul 7.
Protective role of protease-activated-receptor 2 against influenza viruses occurs through an ERK independent pathway : implication for new influenza therapy.
Foucault ML, Moulès V, Ferraris O, Lina B, Rosa-Calatrava M, Riteau B.
Options for the Control of Influenza VII, Influenza and Other Respiratory Viruses, 5(supp.1), 230-251
Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles.
Moulès V, Terrier O, Yver M, Riteau B, Moriscot C, Ferraris O, Julien T, Giudice E, Rolland JP, Erny A, Bouscambert-Duchamp M, Frobert E, Rosa-Calatrava M, Pu Lin
Y, Hay A, Thomas D, Schoehn G, Lina B.
Virology. 2011 May 25;414(1):51-62. doi: 10.1016/j.virol.2011.03.011. Epub 2011 Apr 5.
Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall
down-regulation of the host p53 pathway.
Terrier O1, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N'guyen C, Lina B, Diaz JJ, Bourdon JC, Rosa-Calatrava M.
Virol J. 2011 Jun 8;8:285. doi: 10.1186/1743-422X-8-285.
Role for proteases and HLA-G in the pathogenicity of
influenza A viruses.
Foucault ML, Moules V, Rosa-Calatrava M, Riteau B.
J Clin Virol. 2011 Jul;51(3):155-9. doi: 10.1016/j.jcv.2011.04.013. Epub 2011 May 25.
A new material for airborne virus filtration.
Tiliket G, Le Sage D, Moules V, Rosa-Calatrava M, Lina B, Valleton JM, Nguyen QT, Lebrun l.
Chemical Engineering Journal 173 (2011) 341-351.
Gene expression
signature-based screening identifies new broadly effective influenza a antivirals.
Josset L, Textoris J, Loriod B, Ferraris O, Moules V, Lina B, N'guyen C, Diaz JJ, Rosa-Calatrava M.
PLoS One. 2010 Oct 4;5(10). pii: e13169. doi: 10.1371/journal.pone.0013169.
In vitro characterization of naturally occurring influenza H3NA- viruses lacking the NA gene segment: toward a new mechanism of viral resistance?
Moules V, Ferraris O, Terrier O, Giudice E, Yver M, Rolland JP, Bouscambert-Duchamp M, Bergeron C, Ottmann M, Fournier E, Traversier A, Boule C, Rivoire A, Lin Y,
Hay A, Valette M, Marquet R, Rosa-Calatrava M, Naffakh N, Schoehn G, Thomas D, Lina B.
Virology. 2010 Sep 1;404(2):215-24. doi: 10.1016/j.virol.2010.04.030.
Purification of ribosomes from human cell lines.
Belin S, Hacot S, Daudignon L, Therizols G, Pourpe S, Mertani HC, Rosa-Calatrava M, Diaz JJ.
Curr Protoc Cell Biol. 2010 Dec;Chapter 3:Unit 3.40. doi: 10.1002/0471143030.cb0340s49.
Isolation of nucleoli.
Hacot S, Coute Y, Belin S, Albaret MA, Mertani HC, Sanchez JC, Rosa-Calatrava M, Diaz JJ.
Curr Protoc Cell Biol. 2010 Jun;Chapter 3:Unit3.36. doi: 10.1002/0471143030.cb0336s47.
Cold oxygen plasma technology efficiency
against different airborne respiratory viruses.
Terrier O, Essere B, Yver M, Barthélémy M, Bouscambert-Duchamp M, Kurtz P, VanMechelen D, Morfin F, Billaud G, Ferraris O, Lina B, Rosa-Calatrava M, Moules
V.
J Clin Virol. 2009 Jun;45(2):119-24. doi: 10.1016/j.jcv.2009.03.017. Epub 2009 Apr 29.
Parainfluenza virus type 5 (PIV-5)
morphology revealed by cryo-electron microscopy.
Terrier O, Rolland JP, Rosa-Calatrava M, Lina B, Thomas D, Moules V.
Virus Res. 2009 Jun;142(1-2):200-3. doi: 10.1016/j.virusres.2008.12.017. Epub 2009 Jan 29.
The C-terminal domains of adenovirus serotype 5 protein IX assemble into an antiparallel structure on the facets of the capsid.
Fabry CM, Rosa-Calatrava M, Moriscot C, Ruigrok RW, Boulanger P, Schoehn G.
J Virol. 2009 Jan;83(2):1135-9. doi: 10.1128/JVI.01808-08. Epub 2008 Nov 12.
